SPECIAL ARTICLE

Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus

J.I. Mann (coordinator), Dunedin, New Zealand; I. De Leeuw, Antwerp, Belgium; K. Hermansen, Aarhus, Denmark; B. Karamanos, Athens, Greece; B. Karlström, Uppsala, Sweden; N. Katsilambros, Athens, Greece; G. Riccardi, Naples, Italy; A.A. Rivellese, Naples, Italy; S. Rizkalla, Paris, France; G. Slama, Paris, France; M. Toeller, Düsseldorf, Germany; M. Uusitupa, Kuopio, Finland; B. Vessby, Uppsala, Sweden, on behalf of the **Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD)**

Introduction

The Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) has issued a series of updated statements regarding the nutritional management of patients with diabetes (1-3). These have been based on the best available evidence derived from the scientific literature and the collective clinical experience of members of the group. Recently a more formal approach has been recommended for the development of evidence-based guidelines. This 2004 update has utilised the set of procedures suggested by the Agency for the Health Care Policy and Research and the Scottish Intercollegiate Guidelines Network (4). In brief this involves a formal search of the literature using an agreed set of descriptors and the relevant data banks (*eg* Medline, Embase). For each potential recommendation relevant research studies are assigned to 1 of 5 evidence classes (Table 1), according to type and quality of study (indicated by Roman numerals, in round brackets, after the reference number). A separate evidence class (IV) is reserved for statements from expert committees. The recommendations themselves are graded according to the strength of evidence. Grade A recommendations are based upon evidence classes Ia or Ib, grade B recommendations on evidence classes IIa, IIb or III, and Grade C on evidence class IV. Ideally evidence-based guidelines are based on clinical trials with fatal and non-fatal clinical endpoints. Where such information is not available recommendations are based on the agreed surrogate endpoints listed in Table 2. The criteria used for evaluating individual studies are shown in Table 3. The important role of regular physical activity as a component of lifestyle approaches to the treatment and prevention of diabetes is acknowledged but is not considered in this report. The report also does not include detailed issues relevant to the implementation of the nutritional recommendations in the different European countries, nor does it provide specific recommendations for diabetic patients in particular situations (*eg* pregnancy, critical illness). A recent Cochrane Collaboration [5 (Ia)] concluded that there were no high quality data regarding the efficacy of the dietary treatment of type 2 diabetes mellitus (T2DM). However this article included only those studies which continued for longer than 6 months. Many of these did indeed have design flaws or were characterised by poor compliance. However the DNSG considers that many appropriately designed studies of shorter duration are highly relevant in determining the potential of dietary modification to influence glycaemic control and risk of complications (Table 2).

Previous recommendations have dealt only briefly with the issue of reduction of diabetes risk. The publication of several recent randomised controlled trials has enabled firmer recommendations than were previously possible regarding the role of lifestyle change in the prevention of T2DM (6, 7).

TABLE 1

Evidence classes and grades of recommendations suggested by the Scottish Intercollegiate Guidelines Network (SIGN).

SIGN statements of evidence	SIGN grades of recommendations
Ia Evidence obtained from meta-analysis of randomised controlled trials.	A Requires at least one randomised controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation. (Evidence levels Ia, Ib)
Ib Evidence obtained from at least one randomised controlled trial.	
IIa Evidence obtained from at least one well-designed controlled study without randomisation.	B Requires the availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation. (Evidence levels IIa, IIb, III)
IIb Evidence obtained from at least one other type of well-designed quasi-experimental study.	
III Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies.	
IV Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities.	C Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV)

Energy balance and body weight

Recommendations

– For those who are overweight (BMI >25 Kg/m^2), caloric intake should be reduced and energy expenditure increased so that BMI moves towards the recommended range. Grade A

– Prevention of weight regain is an important aim once weight loss has been achieved (Grade A). Those who are overweight or obese and are unable to loose weight should be strongly encouraged to take measures to avoid further weight gain. Grade C

– For those with a body mass index (BMI) in the recommended range for adults (18.5-25 Kg/m^2), it is usually unnecessary to prescribe energy intake. Grade C

– The amount of physical activity needs to be taken into account when considering recommendations regarding total energy. Grade C

– Advice concerning the reduction of energy dense foods, in particular those high in saturated fat and free sugars, will usually help to achieve weight loss without the need for precise energy prescription. Grade C

– If these measures do not achieve the desired weight reduction, more precise advice may be required to achieve an energy deficit sufficient to loose weight at an appropriate rate. Grade C

Commentary

The mortality rates in diabetic individuals in the American Cancer Association Study [8 (III)] were dramatically increased when body mass index (BMI) exceeded 25 Kg/m^2. Data from the Nurses Health Study suggest a graded increase of risk as BMI rises above 22 Kg/m^2 which is exaggerated in those with diabetes [9 (III)]. Thus it seems reasonable to assume that the appropriate range for BMI in people with diabetes is similar to that (18.5-25 Kg/m^2) recommended for non-diabetic individuals [10-12 (Ia)]. Amongst the overweight, insulin sensitivity is decreased and there is a deterioration in most aspects of diabetes control [3 (IV), 13 (Ia)]. Even modest weight loss of under 10% body weight improves insulin sensitivity and glucose tolerance and reduces lipid levels and blood pressure [14, 15(Ib)]. The reduced life expectancy of overweight people with diabetes is improved in those who lose weight and may even be normalised without achieving a BMI under 25 Kg/m^2 [16, 17 (IIb)]. Maintenance of weight loss is an important goal of therapy (18, 19). Diabetic patients have a high proportion of intraabdominal fat and associated increased health risks related to insulin resistance and associated dyslipidaemia and hypertension (20). Weight loss may lead to greater improvements in cardiac risk factors in individuals with a high waist/hip ratio or waist circumference (21). Prevention and treatment of obesity have become a major public health issue, worldwide [22, 23 (IV)].

Overweight patients with type1 diabetes mellitus (TIDM) may also become insulin resistant and weight loss may lead to a reduction in insulin dose and improved glycaemic control (24, 25).

TABLE 2
Surrogate endpoints used in nutritional studies involving
people with diabetes.

Glycaemia	Fasting plasma glucose
	Post-prandial plasma glucose
	Glycated haemoglobin (HbA$_{1c}$)
Body composition	Adiposity
	Body weight
	Body mass index (BMI)
	Waist circumference
Lipoprotein profile	Total cholesterol
	LDL-cholesterol
	HDL-cholesterol
	Triglyceride
Blood pressure	
Insulin sensitivity	Fasting insulin
	Post-prandial insulin
	Insulin sensitivity index (ISI)
	Whole body glucose disposal
Renal function	Microalbuminuria
	Proteinuria
	Glomerular filtration rate

Protein

Recommendations

– In patients with no evidence of nephropathy, protein
  intake may provide 10-20% total energy. Grade B
– In patients with T1DM and evidence of established
  nephropathy, protein intakes should be at the lower
  end of the acceptable range (0.8 g/kg normal body
  weight/day). Grade A
– For patients with T1DM and incipient nephropathy
  (microalbuminuria) and those with T2DM and estab-
  lished or incipient nephropathy, there is insufficient evi-
  dence to make a firm recommendation regarding pro-
  tein restriction. Grade C
– There is insufficient evidence to make recommendations
  about the preferred type of dietary protein. Grade C

Commentary

Protein intake in most western populations ranges
between 10 and 20% total energy. In patients with both
T1DM and T2DM protein contributes 15-20% total daily
energy intake which corresponds to 1.3-2.0 g/Kg body
weight. This represents an intake which exceeds require-
ments and is greater than the age-matched general popu-
lation (26-29). Four cross sectional studies have not

shown an association between protein intakes in the
usual range and presence of microalbuminuria in T1DM
[30-33 (III)]. However in T1DM patients with protein
intake more than 20% total energy, the albumin excre-
tion rate increases with increasing protein intake espe-
cially when hypertension and/or poor glycaemic control
are also present [34 (III)]. Glomerular hyperfiltration is
present in many T1DM patients at diagnosis but its sig-
nificance as a risk factor for future diabetic nephropathy
has not been established and furthermore in cross-sec-
tional studies no correlation has been found between
protein intake and glomerular filtration rate (GFR) (35,
36). Limited information is available concerning T2DM.
Two cross sectional studies showed no association
between protein intake and microalbuminuria or
Albustix positive proteinuria [37, 38 (III)].

In T1DM patients with evidence of established renal
disease several randomised controlled trials have con-
firmed the potential benefit of protein restriction. A
metaanalysis of five randomised control trials (RCT's) in
T1DM, of up to three years duration, showed that a low
protein diet significantly slowed the development of
albuminuria and the decrease of GFR [39 (Ia)]. In four
RCT's, each one comprising from 15 to 35 T1DM
patients with diabetic nephropathy and a follow-up rang-
ing from 3 weeks to 3 years, a significant reduction in
both albuminuria and the rate of GFR decrease has been
documented (40-43). In the most recent randomised con-
trolled trial involving 82 patients, the longest carried out
thus far (4 years), the T1DM patients randomised to the
low protein treatment (target intake: 0.6 g/Kg/day;
achieved intake 0.89 g/Kg/day) had a strikingly improved
outcome (relative risk for end stage renal disease or
death, after adjustment for cardiovascular risk factors:
0.23) compared with those randomised to usual protein
intake (1.2 g/Kg/day) [44 (Ib)]. Thus protein restriction is
recommended for diabetic nephropathy in T1DM.
However patients with diabetes, especially when poorly
controlled or on haemodialysis, have increased protein
turnover and their protein requirements may be greater
than the recommended daily allowances (RDA) (45-48).
Thus protein intake should not be reduced below 0.6
g/kg normal body weight/day because it may lead to mal-
nutrition. Studies of protein restriction in patients with
T1DM and incipient nephropathy (microalbuminuria)
have shown inconsistent results. Small (5-7 µg/min), but
significant decreases in albumin excretion rate (AER)
were observed on low protein diets in two studies but no
relation was found in another (49-51). In RCT's of a few

<center>**TABLE 3**
Criteria for evaluating individual studies relevant to recommendations for people with diabetes.</center>

• Surrogate endpoints must be appropriate (see Table 2) if fatal or clinical endpoint data not available
• Type of diabetes and treatment must be specified
• Subjects must be representative of relevant patient group
• In experimental studies, subjects should be randomised to control or experimental diets
• Experimental studies will usually involve parallel or cross over design, depending upon endpoint being investigated
• Nutrition intervention must be clearly specified and methods of assessing compliance stated when studies involve free-living individuals
• Duration must be appropriate to the endpoint under consideration. In general studies carried out for weeks or months are preferable to acute meal experiments
• Epidemiological studies (which will usually be cohort or comparative studies) must utilise validated dietary instruments and in the case of cohort studies should preferably be based on more than a single period of assessment
• Statistical methods must be clearly described and appropriate
• Methods for identifying appropriate studies (*eg* descriptors and search engines) must be specified

weeks duration, low protein diets reduced GFR in hyperfiltering patients with no effect on microalbuminuria (52, 53). In two RCT's in T2DM patients with microalbuminuria, proteinuria or overt nephropathy, protein restriction had no effect on albuminuria or GFR (54, 55), while in a randomised crossover study of 12 T2DM patients with microalbuminuria, a decrease of both GFR and microalbuminuria was observed (56). Although well planned and conducted, the above studies were of short duration and used surrogate endpoints (albuminuria, hyperfiltration) rather than end stage renal disease or death and thus their results cannot support valid recommendations.

Several studies have examined the source and quality of protein on renal function. In T1DM patients, a vegetable protein diet decreased GFR in one study (57) and albumin excretion rate in another (58). However in a RCT in T2DM patients with microalbuminuria, 6 weeks vegetable protein diet compared with animal protein diet had no effect on AER (59). In T1DM patients substitution of half of the protein intake with soy protein resulted in decrease of the urinary albumin excretion in one study (60), but showed no effect in another (61). In a case control study in T1DM patients, high fish protein intake was associated with a decreased risk of microalbuminuria (62). In randomised controlled crossover trials in T1DM patients, substitution of red meat with chicken for 4 weeks reduced GFR to the same extent as a low protein diet in hyperfiltering patients and in addition

reduced the AER in patients with microalbuminuria (63, 64). However given the short duration of these studies and lack of clinical endpoints no recommendations are offered at present regarding nature of dietary protein.

Dietary fat

Recommendations
– Saturated and trans-unsaturated fatty acids should provide under 10% total daily energy. A lower intake (< 8% total energy) may be beneficial if LDL-cholesterol is elevated. Grade A
– Oils rich in monounsaturated fatty acids (MUFA) are useful fat sources and depending upon individual preferences MUFA may provide 10 to 20% total energy, provided total fat intake does not contribute more than 35% total energy. Grade B
– Polyunsaturated fatty acids (PUFA) should not exceed 10% total daily energy. Grade C
– Total fat intake should not exceed 35% total energy. Grade C
– For those who are overweight, fat intake below 30% may facilitate weight loss. Grade C
– Consumption of two to three servings of fish (preferably oily fish) each week and plant sources of n-3 fatty acids (*eg* rapeseed oil, soybean oil, nuts and some green leafy vegetables) will help to ensure an adequate intake of n-3 fatty acids. Grade B

– Cholesterol intake should not exceed 300 mg/day and be further reduced if LDL-cholesterol is raised. <u>Grade A</u>

Commentary

The recommendations on dietary fat intake in diabetes mellitus are mainly based on studies in non-diabetic subjects, including controlled dietary studies and epidemiological studies. There are no controlled dietary intervention studies in subjects with diabetes with sufficient power to demonstrate effects of dietary fat on cardiovascular or other disease endpoints, and very limited data from observational studies on the relationships between dietary fat intake and disease or death in subjects with diabetes. There are a number of studies comparing diets with a higher fat content (mainly due to an increased content of MUFA) with those containing a higher proportion of carbohydrates, and a number of controlled studies investigating the effect of the type of dietary fat in people with diabetes. Such studies which compare the effects of modifying fat intake on disease risk factors or surrogate endpoints (*eg* serum lipid or lipoprotein concentrations, adiposity, glycaemia, insulin sensitivity) complement the data from studies in non-diabetic individuals.

It is deemed to be appropriate to consider studies in "healthy" non-diabetic subjects when developing nutritional recommendations for people with T2DM as the delineation between healthy subjects with obesity and/or traits of the metabolic syndrome and T2DM is based on an arbitrarily chosen limit for blood glucose. All evidence indicates that the development of diabetes is a process which occurs over years or decades including a gradual impairment of insulin sensitivity and development of associated metabolic derangements. The risk for cardiovascular complications is high prior to the diagnosis of diabetes and the same risk factors are present before as after the diagnosis, although the importance of the risk factors is even more pronounced in diabetic patients. All available data suggest that the same dietary changes, which are documented to reduce the risk for cardiovascular disease in the non-diabetic population, are even more relevant in the diabetic population, as the risk factors are associated with an even higher risk in subjects with diabetes. Although the pathogenesis of T1DM differs from that of T2DM, most of the risk factors for cardiovascular disease shown to operate in healthy individuals and T2DM also appear to be relevant to T1DM. Thus broadly similar recommendations are given for T1DM and T2DM.

The major recommendation offered concerning total fat is that intake should not exceed 35% total energy due to the risk of increased body weight on high fat diets [65(Ia)]. In addition on a high total fat intake there may be an adverse effect on insulin sensitivity regardless of the nature of dietary fat, as suggested in a study of healthy individuals [66 (Ib)]. For most individuals a wide range of intakes is acceptable and will depend upon individual preferences and characteristics. For those who are overweight a total fat intake below 30% total energy may facilitate weight loss [3 (IV)].

Saturated fatty acids

There is convincing evidence from meta analyses of controlled trials in those without diabetes [67-69 (Ia)] that an exchange of dietary saturated fatty acids with unsaturated fatty acids (other than trans fatty acids – see below) or carbohydrates will reduce LDL-cholesterol. That an exchange of saturated fatty acids by unsaturated fatty acids will lower LDL-cholesterol has support also in a few controlled studies in subjects with diabetes [70 (Ib)] and glucose intolerance [71 (Ib)]. Recently, three controlled dietary intervention studies performed under isoenergetic conditions in healthy [72, 66(Ib)] and obese (some of them also with diabetes) subjects [73(Ib)] indicate that an exchange of saturated fatty acids with unsaturated fatty acids in the diet will significantly improve insulin sensitivity. Although little is known about the metabolic effects of the different saturated fatty acids in diabetes it has been clearly demonstrated that stearic acid, in contrast to other saturated fatty acids (lauric, myristic and palmitic) does not increase cholesterol (74). Furthermore it seems likely that those with diabetes, as is the case in those who do not have the condition, will show a greater increase in total and LDL-cholesterol when myristic and palmitic acids are compared with lauric acid (75).

Saturated fatty acids may also induce a detrimental postprandial lipid profile compared with monounsaturated fat in both normal (76) and diabetic [77 (Ib)] subjects. Saturated fatty acids and trans fatty acids induced an increase in postprandial insulinaemia in obese subjects with T2DM [78 (Ib)]. In two prospective studies of diabetic subjects [79, 80 (III)], the proportion of saturated fatty acids in the diet (or P/S-ratio) was significantly associated with the incidence of new coronary heart disease events. Several prospective studies [81-83 (III)] indicate that a high proportion of saturated fatty acids in the plasma lipid esters, compatible with a high dietary intake of saturated fatty acids, are related to an increased risk of developing T2DM. In observational studies [84-89 (III)] a clear association between saturated fat in the diet and diabetes development is, however, not found after adjustment for BMI.

Trans unsaturated fatty acids

A metaanalysis [90 (Ia)] and controlled dietary studies in those without diabetes demonstrate adverse effects by dietary trans fatty acids on LDL-cholesterol, HDL-cholesterol, LDL size and the Lp(a) levels. Trans fatty acids induced an increase in post-prandial insulinaemia in obese subjects with T2DM [78 (Ib)]. Some observational studies suggest that a high intake of trans fatty acids may increase the risk of developing T2DM [87 (III)]. However, the content of trans fatty acids of the diets in the observational studies are not well characterized.

Monounsaturated fatty acids

Substituting monounsaturated for saturated fatty acids has beneficial effects on serum lipid levels and on lipoprotein concentration and composition [67-69(Ia)] and also on insulin sensitivity in glucose intolerant (71) or healthy subjects provided that the total fat intake is not too high [66 (Ib)]. There are also controlled studies indicating that substituting a certain amount of monounsaturated fat (MUFA) for carbohydrates may confer some benefit regarding serum lipid levels, if the source of carbohydrates is mainly starch rich foods with a low content of dietary fibre and high glycaemic index [91 (Ia)]. This may mainly relate to normal weight diabetic subjects, possibly especially T1DM. There is, on the other hand, no convincing evidence that a shift from a diet high in carbohydrate rich foods with a high fibre content and low glycaemic index to a diet containing more MUFA will improve metabolic control in diabetes (72, 76, 92-95). Such a change might rather increase the risk of weight gain due to increased energy intake. Compliance with a low fat diet containing a high proportion of high-fibre, low glycaemic index carbohydrate may promote weight loss and metabolic improvement in subjects with T1DM (96), the metabolic syndrome (97) and glucose intolerance (98). In some intervention studies in T2DM a high intake of MUFA seems to be associated with a lower blood pressure than a diet with a higher proportion of PUFA (99) or carbohydrates (100). Oils rich in MUFA are thus useful fat sources and, depending upon metabolic features and individual preferences, MUFA may provide 10-20% total energy provided that fat intake does not exceed 35% total energy.

n-6 polyunsaturated fatty acids

Substituting PUFA for saturated fatty acids has beneficial effects on serum lipid levels and lipoprotein concentration and composition [67- 69 (Ia)] and insulin sensitivity [73 (Ib)]. With regard to both blood glucose and blood lipid levels in T1DM and T2DM, there appears to be little difference when sources of mono- and PUFA are compared (101). Prospective studies indicate that a high proportion of polyunsaturated vegetable (linoleic acid rich) fat in the diet [84, 85, 88 (III)], or a high proportion of linoleic acid in the plasma lipid esters [81-83 (III)] indicating a high dietary intake, is associated with a reduced risk of developing T2DM. A high P/S ratio has been associated with a low risk of fatal cardiovascular events in people with diabetes [79, 80 (III)]. However it has been suggested that the intake of linoleic acid in the diabetic diet be limited to less than 10% of the energy intake, because of the possibility that higher intakes might increase the risk of lipid peroxidation in the body. Direct evidence for such a recommendation [3 (IV)] is lacking, but it is offered as practical advice in the interests of safety. Furthermore a higher intake is unrealistic given the much lower intakes of PUFA in most European countries (102).

n-3 fatty acids

Observational evidence supports the recommendation that intake of fish and intake of n-3 fatty acids from plant sources (alpha linolenic acid) may reduce the risk of cardiac death and stroke [103, 104 (III)]. Supplementation with n-3 fatty acids in diabetes reduces serum triglyceride levels, but may simultaneously be associated with a moderate increase in LDL-cholesterol [105 (Ia)]. It has been suggested that supplementation with long-chain n-3 fatty acids may increase blood glucose levels, but recent meta analyses [106, 107 (Ia)] indicate that this effect is negligible. There are no published controlled studies to suggest that supplementation with n-3 fatty acids in humans will improve insulin sensitivity. Women with diabetes and a high regular fish consumption have a lower incidence of coronary heart disease and a decreased mortality rate compared with those with a lower intake [108 (III)]. Although current evidence supports the recommendations concerning the dietary intake of fish and n-3 fatty acids from plant sources, there is at present no consensus on the use of supplements containing n-3 fatty acids in diabetes (see section on Supplements). Furthermore there are insufficient data to make a precise recommendation regarding the optimal ratio of n-3/n-6 fatty acids. However an increased intake of dietary n-3 fatty acids is encouraged in line with current recommendations for the general population.

Dietary cholesterol

Data in non-diabetic subjects [109 (Ia)] and also in T1DM [110 (Ib), 111 (III)] support the recommendation to restrict the cholesterol intake in the diet, as the cholesterol levels in plasma increase with increasing intakes of dietary

cholesterol. In a prospective study of women with diabetes a high intake of cholesterol was related to an increased risk of cardiovascular disease [80 (III)]. In the EURODIAB Complications Study increased intakes of total fat, saturated fat and cholesterol were significantly related to higher prevalences of cardiovascular disease. These associations were, however, no longer significant after adjustment for dietary fibre intake for which an independent association with the serum cholesterol pattern and cardiovascular diseases (CVD) has been demonstrated [111 (III)].

Carbohydrate

Recommendations
– Carbohydrate intake may range between 45% and 60% total energy. Grade C
– Metabolic characteristics suggest the most appropriate intakes within this range for individuals with T1DM and T2DM. Grade A
– Vegetables, legumes, fruits and wholegrain cereals should be incorporated into the diet of people with T1DM and T2DM. When carbohydrate intake is at the upper end of the recommended range it is particularly important to emphasise foods rich in dietary fibre and with a low glycaemic index. (See recommendations on fibre, glycaemic index and micronutrients). Grade A
– There is no justification for the recommendation of very low carbohydrate diets in persons with diabetes (see recommendations on fat). Grade B
– Carbohydrate quantities, sources and distribution throughout the day should be selected to facilitate near-normal long-term glycaemic control (HbA1c-levels). In those treated with insulin or oral hypoglycaemic agents timing and dosage of the medication should match quantity and nature of carbohydrate. Grade C

Commentary
The recommended range of carbohydrate (CHO) intake (45-60% total energy) is based on the limits for total fat and protein intakes (see recommendations on protein and fat intake in this paper), [3, 28, 112-113 (IV)]. A meta-analysis [91 (Ia)] compared the effects of high carbohydrate diets (49-60% CHO, 20-32% fat, 7-13% MUFA) with diets higher in monounsaturated fat and lower in carbohydrate (36-40% CHO, 37-50% fat, 22-33% MUFA) on serum lipids and glycaemic control in persons with T2DM. Several of the studies involved high carbohydrate diets which were rich in starchy foods rather than fibre-rich low

glycaemic index foods. Only randomised crossover trials [100, 114-121 (Ib)] using iso-energetic, weight-maintaining diets were considered. The trials involved 8 to 42 persons with T2DM (in- or outpatients on diet alone, different oral agents and insulin treatment); study length was 2-6 weeks.

Compared with a high carbohydrate diet, a high monounsaturated fat, lower carbohydrate diet resulted on average in a 19% reduction of serum triglycerides [significant in 5 studies, not significant in 3 studies (117, 120, 121), no change in 1 study (100)], a 4% increase in HDL-cholesterol [increase in 5 studies, no change in 4 studies (100, 118, 120, 121)], a 3% decrease in total cholesterol [decrease in 6 studies, no change in 1 study (121), increase in 2 studies (115, 117)] and no net-change in LDL-cholesterol. The net-lowering of fasting blood glucose concentrations was -4 mg/dL with the high monounsaturated fat diet ($p<0.05$); no change was seen in fasting insulin concentrations. Effects on mean preprandial plasma glucose was either significantly reduced (114) or unchanged (116). Five studies reported a significant reduction of post-prandial blood glucose concentrations in the patients with a high MUFA lower carbohydrate diet, but none of the studies showed a significant reduction in HbA_{1c} or fructosamine compared with those on a high carbohydrate diet. Thus the long-term effect on glycaemic control was comparable on both the moderate to high carbohydrate diet (49-60%) and the low to moderate carbohydrate diet (37-50%) respectively. This meta-analysis shows that a wide range of carbohydrate intakes is compatible with overall comparable glycaemic control in persons with T2DM [91 (Ia)]. The untoward effects of relatively high starch intakes on fasting triglycerides and possibly on postprandial glucose concentrations observed in some of the studies included in this metaanalysis can be avoided if the carbohydrate-containing foods are rich in dietary fibre and/or have a low glycaemic index (122, and see sections on fibre and glycaemic index). The range of recommended carbohydrate intake is also suitable in T1DM [123 (Ib)], particularly when fruits, vegetables and whole grain cereal foods are a part of the diet [124 (III)].

Some persons with T2DM may show improved lipid levels when carbohydrate intake is at the lower end of the recommended range [114, 115, 116, 118, 119, 121, (Ib)] so that for those with persistently raised triglyceride levels a trial of intake at the lower end of the recommended intake range may be appropriate. This may also be tried in T1DM persons with hypertriglyceridemia [125 (Ib)].

There is no long-term evidence of benefit of low or very low carbohydrate diets. Such diets would be undesirably high in fat and could increase body weight and decrease

insulin sensitivity [66 (Ib), 96 (III), 126 (III)]. Low carbohydrate, high fat diets have not been shown to achieve long-term weight loss [127, 128 (Ib)]. Given the high percentage of saturated fatty acids (14% of total energy and more) in the diets of persons with diabetes throughout the European countries at present [28, 111(III), 112] such diets may induce raised levels of total and LDL-cholesterol (see recommendations on fat intake). In addition, there is no evidence on which to base a recommendation that protein intake should be more than 20% of total energy in order to reduce carbohydrate. Many foods high in protein are also high in saturated fat, and it seems inappropriate to promote a food pattern characterised by a high fat intake to persons with diabetes in European countries where high intakes of total and saturated fat predominate [29, 96, 102, 129, 130, (III)].

Besides ensuring desirable nutrient intakes in those with T1DM and T2DM it should be noted that appropriate quantities, sources and distribution of carbohydrate-containing foods can facilitate near-normal long-term metabolic control [124, 131-134 (III)]. The selection of carbohydrate quantities and sources as well as the distribution of these foods throughout the day may be guided by blood-glucose self-monitoring of the person with diabetes [3, 135, 136 (IV)]. Those who need oral hypoglycaemic agents in addition to nutritional therapy should be aware of the mode of action of their medication and the optimal timing of the intakes of tablets, meals and snacks. Persons with diabetes who are treated with insulin should be informed about the duration of action of their injected insulins to optimise the match between quantity and nature of carbohydrate and insulin dosage [113 (IV), 137 (III), 138, 139 (IV)]. For most patients those with T1DM and those with T2DM on insulin or oral agents it is usually possible to adjust therapy according to amount and type of carbohydrate so that it is possible for patients to include a variety of carbohydrate sources in their diet without deterioration in glycaemic control [124 (III)]. When choosing carbohydrate containing foods their effect on insulin sensitivity, serum lipids and energy balance should be considered [96, 97, 140, 141 (III)]. The effects of fibre, glycaemic index and content of sugars on these important predictors of health outcome are discussed in more detail in the sections which follow. However, it is relevant to note here that regular consumption of vegetables, legumes, intact fruits and wholegrain cereals should be part of the diet in people with T1DM and T2DM as these foods help to ensure adequate fibre and micronutrient intakes, do not promote hypertriglyceridaemia and may facilitate weight reduction by promoting satiety [142, 143 (III)]. Thus these foods should be especially emphasized for those who are overweight or obese, those with the metabolic syndrome and those who have a preference for relatively high intake of carbohydrate.

Dietary fibre

Recommendations
– People with T1DM and T2DM should be encouraged to consume naturally occurring foods that are rich in dietary fibre. Grade A
– Dietary fibre intake should ideally be more than 40 g/day (or 20 g/1000 Kcal/day), about half of which should be soluble. Beneficial effects are also obtained with lower, and for some, more acceptable amounts. Grade A
– Daily consumption of at least 5 servings of fibre-rich vegetables or fruit and at least 4 servings of legumes per week can help to provide minimum requirements for fibre intake. Grade C
– Cereal-based foods should, whenever possible, be wholegrain and high in fibre. Grade B

Commentary
In the 1980's short term randomised controlled studies (involving cross-over designs) were conducted in patients with T1DM and T2DM using two diets comprising naturally occurring foods but differing in the amounts of dietary fibre (16 g/day compared with 54 g/day, mainly soluble fibre). Average daily blood glucose levels were reduced by 10-15% and postprandial levels by 25% on the high fibre diet [144, 145 (Ib)]. Also during the 1980's other controlled trials in T1DM and T2DM compared the effects of high carbohydrate-high fibre diets (more than 50 g/day, at least 50% soluble fibre) with the then-conventional lower carbohydrate-low fibre diets. Again, the high carbohydrate-high fibre diets were associated with improved glycaemic control, including lower levels of HbA$_{1c}$ [146, 147 (Ib)]. Since other studies carried out in the same time period showed no benefit or a detrimental effect on glycaemic control when a low carbohydrate diet was compared with a high carbohydrate-high starch-low fibre diet [148, 149, 150 (Ib)], the beneficial effect is attributed to the high fibre intake [151, 152]. Two recent randomised controlled trials of longer duration have been carried out in T1DM (parallel design) and T2DM (cross-over design). Sixty patients with T1DM were randomised to 2 diets which differed only with regard to amount of dietary fibre and followed as outpatients for 6 months. The high fibre diet was associated with a reduced number of hypo-

glycaemic events, improved mean daily and postprandial glucose levels, and in the 83% of compliant patients a reduction in HbA$_{1c}$ [153 (Ib)]. Although 50 g fibre/day was recommended, in practice only 40 g/day (half of the soluble type, from legumes, fruit and vegetables) was consumed. The other study performed in patients with T2DM [154 (Ib)] shows very similar results: 10% reduction in the average blood glucose, 25% in postprandial blood glucose and also a significant decrease in daily insulin levels. Thus, the ideal amount of dietary fibre appears to be 40 g/day (about 20 g/1000 Kcal/day) or more, half of which is soluble. However beneficial effects are also obtained with lower, and for some, more acceptable amounts.

The few studies showing no effect of high fibre diets on blood glucose control utilised diets rich in insoluble fibre (155). Cross sectional epidemiological data based on the EURODIAB Complications Study which included over 2000 patients with T1DM in 31 European centres showed an inverse association between dietary fibre intake and HbA$_{1c}$ which was independent of possible confounders. Risk of ketoacidosis was reduced in association with a high fibre intake [131 (III)].

Most of the randomised trials referred to above have also studied the effects of dietary fibre on lipids and lipoproteins. Several [143, 145, 146, 154 (Ib)], though not all (153), of the studies involving diets rich in soluble fibre have found lower levels of total and LDL-cholesterol on the high fibre diets. None have shown a deleterious effect. Cross sectional data from the EURODIAB Complications Study show an inverse association between dietary fibre and LDL-cholesterol (in men only) and a positive association between fibre intake and HDL-cholesterol (in both men and women) [156 (III)].

Dietary fibre intake has been inversely and significantly related to cardiovascular disease in a cross sectional study in T1DM [156 (III)] and in several prospective studies of non-diabetic individuals [157-160 (III)]. Dietary fibre is also associated with lower levels of BMI in T1DM (96) and prospectively in those without diabetes (161) and with higher insulin sensitivity in the non-diabetic population (162).

Glycaemic index

Recommendations
– Carbohydrate-rich, low glycaemic index foods are suitable as carbohydrate-rich choices provided other attributes of the foods are appropriate. <u>Grade A</u>

Commentary
The glycaemic index (GI) is defined as the incremental blood glucose area following ingestion of 25-50 g available carbohydrates expressed as a percentage of the corresponding area following ingestion of carbohydrate from a reference food (glucose or white bread). Both type and amount of carbohydrate influence the glycaemic response [133, 141 (III)]. Whether or not the cellular structure remains intact is also relevant (163). Thus in practice the actual carbohydrate load from a normal portion size varies considerably. In order to address this problem, the concept of glycaemic load (GL) was introduced. GL, calculated as the amount of carbohydrate in one serving multiplied by the GI of the food, allows comparisons of the likely glycaemic effects of realistic portions of different foods [164 (IV)]. There is, however, considerable variability within and between subjects in glucose response to the same glycaemic load on different days (165, 166).

A number of controlled dietary intervention studies comparing diets containing high GI and low GI foods have been undertaken with varying results [93, 153, 167-175 (Ib)]. A recent meta-analysis [176 (Ia)] reported an improvement of the mean blood glucose control, with an average reduction of HbA$_{1c}$ by 0.43% on a low, compared with a high GI diet in diabetic subjects. Although the effect of a low GI diet on glycaemic control is smaller than that observed with other dietary interventions, it should not be considered trivial since it was achieved over and above that of other dietary changes such as reduction of total carbohydrates, increased fibre intake or body weight reduction [177, 178 (IV)]. It is similar to that achieved by some glucose-lowering medications and consistent with findings from the Eurodiab Complications Study, which showed that the GI of the diet was positively and independently related to HbA$_{1c}$ levels [132 (III)].

When reviewing the results of intervention studies, there is no uniform evidence for beneficial effects on blood lipid levels by low GI diets. However in one well controlled study in T2DM subjects [174 (Ib)] there was a significant reduction of LDL-cholesterol, and of PAI-1 on the low GI diet indicating an improvement compared with a high GI diet. Another more recent 4- week study has shown additionally the potential for a low GI diet to enhance glucose utilisation and improve the capacity for fibronolysis in T2DM [179 (Ib)].

The GI concept should in principle be used to classify carbohydrate-rich foods, and is only meaningful when comparing foods within a comparable food group, *eg* breads, fruits, different types of pasta or rice. GI values should not

be used in isolation, but interpreted in relation to other relevant food characteristics, *eg* energy content, content of other macronutrients, available carbohydrates, and dietary fibre [132 (III), 180 (IV)]. For example, some foods may be rich in saturated fat and free sugars and have a low GI. Provided all qualities of the food are taken into account, available evidence supports the suggestion that the GI content of food may be a helpful additional indicator regarding the appropriate carbohydrate-containing foods for inclusion in the diet. Despite this qualified support for the use of the GI concept as it relates to natural foods, it should be noted that most studies showing beneficial effects have been relatively short term.

Sucrose and other free sugars[1]

Recommendation
– If desired and if blood glucose levels are satisfactory, moderate intakes of free sugars (up to 50 g/day) may be incorporated within the diet of individuals with T1DM and T2DM. Grade A
– As for the general population intake of total free sugars should not exceed 10% total energy. More restrictive advice concerning free sugars may be useful for those needing to lose weight. Grade C

Commentary
In the 1980's several randomised controlled trials with crossover designs demonstrated no adverse effects on glycaemic control, lipids and lipoproteins when diets containing small amounts of sucrose (usually around 50 g) were compared with virtually sucrose-free diets in T1DM and T2DM [181-183 (Ib), 184]. These studies led to a more liberal approach than that adopted previously when sucrose restriction as far as possible was advised.

While there is clear evidence for the acceptability of moderate intakes of sucrose for most people with diabetes, there are fewer data from which to derive acceptable upper limits. It is necessary to extrapolate recommendations from studies of healthy individuals, overweight and obese subjects and those with the metabolic syndrome using lipid levels and energy balance as surrogate endpoints (185). In

non-diabetic individuals [186 (Ib)] and those with the metabolic syndrome [97 (III)] diets high in sugars have been associated with hypertriglyceridemia when compared, in randomised controlled trials, with diets higher in starches and non-starch polysaccharides. In subjects with the metabolic syndrome the high starch, relatively high fibre diet was associated with weight loss when compared with a diet high in sugars [97 (III)].

Diets including high sucrose containing drinks have been shown to be associated with an increase in energy intake, body weight, fat mass and plasma lipids when compared with diets in which the drinks were artificially sweetened [187 (Ib)]. It appears that humans may have a weak innate ability to recognise sweet drinks and to appropriately down regulate the consumption of such foods in order to maintain energy balance. The resultant overcompensation of energy, regardless of sources, without concomitant increase in energy expenditure will lead to weight gain, reduced insulin sensitivity and associated abnormalities including dyslipidaemia and hypertension. Thus it is clear that excessive consumption of free sugars may indirectly contribute to disturbances which predispose to adverse clinical outcomes. However the recommendation regarding a maximum intake of 10% total energy is somewhat arbitrary and is derived from recommendations of other expert consultations including the Expert Consultation on Diet, Nutrition and the Prevention of Chronic Diseases [23(IV)].

In healthy subjects, high intakes of fructose (17% total energy) are associated with hypertriglyceridaemia [188 (Ib)]. However a moderate intake of fructose (up to 30 g/day) appears to have no deleterious effects in terms of plasma insulin and lipids when included in the diet of people with T2DM [189 (Ib)].

Antioxidant nutrients, vitamins, minerals and trace elements

Recommendation
– Foods naturally rich in dietary antioxidants (tocopherols, carotenoids, vitamin C, flavonoids, polyphenols, phytic acid), trace elements and other vitamins should be encouraged. Grade C
– The daily consumption of a range of vegetables and fruit is encouraged since these are rich sources of many vitamins and antioxidant nutrients. Grade C
– Regular intakes of wholegrain breads, cereals and oily fish facilitate recommended intakes of the remaining water and fat soluble vitamins. Grade C

---

[1]Free sugars are defined as: all monosaccharides and disaccharides added to foods by the manufacturer, cook or consumer, plus sugars naturally present in honey, syrups and fruit juices.

– As in the general population people with diabetes should be advised to restrict salt intake to under 6 g/day. A further restriction may be appropriate for those with elevated blood pressure. <u>Grade A</u>

Commentary

There is a considerable body of evidence from prospective studies in non-diabetic individuals to suggest that a range of antioxidant nutrients and vitamins, and foods rich in them: fruits, vegetables, nuts and berries, protect against cardiovascular disease [190-200 (III)]. Furthermore, regular consumption of wholegrain breads, cereals and oily fish facilitate appropriate intakes of the remaining vitamins [157, 201-204 (III)]. Short-term studies which involve the consumption of foods rich in these nutrients and supplemention with a range of synthetic micronutrients confirm in diabetic and non-diabetic individuals that markers of oxidative stress can be favourably influenced by substantial intakes (205-208). However studies with clinical endpoints (principally carried out in people who do not have diabetes) have thus far not demonstrated beneficial effects. Thus in people with diabetes it seems appropriate to recommend foods rich in such nutrients, but not supplements (209).

Moderate dietary sodium restriction has been shown to produce substantial reduction in systolic blood pressure in mildly hypertensive patients with T2DM [210 (Ib)] and to enhance the blood pressure lowering effect of other dietary manipulations (low fat dairy products, fruits and vegetables) in non-diabetic individuals [211-213 (Ib)].

Between 20 and 25% of people with diabetes have been reported to have low levels of circulating magnesium, especially those with T1DM and poor glycaemic control (214, 215) and those with reduced absorption in autonomic neuropathy or associated autoimmune disease (216). Magnesium depletion of muscle (217) and bone (218) has been observed and linked to retinopathy (219) and polyneuropathy (220). A role for magnesium supplementation in halting the progression of neuropathy and retinopathy, and possibly for all patients with poorly controlled T1DM, has been suggested (221). Magnesium-rich foods may also be considered in this context. However firm recommendations must await confirmation of these observations.

Low levels of zinc and chromium and high levels of copper have been reported in people with diabetes, but there is no evidence to suggest that such observations should influence nutritional recommendations.

Alcohol

Recommendations
– Moderate use of alcohol (up to 10 g/day for women and 20 g/day for men) is acceptable for those with diabetes who choose to drink alcohol. <u>Grade B</u>
– When alcohol is taken by those on insulin it is most appropriately consumed with a meal including carbohydrate-containing food because of the risk of potentially profound and prolonged hypoglycaemia. <u>Grade B</u>
– Alcohol should be limited by those who are overweight, hypertensive or hypertriglyceridaemic. Abstention is advised for women during pregnancy and those with a history of pancreatitis or alcohol abuse, appreciable hypertriglyceridaemia, advanced neuropathy, and erectile dysfunction. <u>Grade C</u>

Commentary

A high proportion of adults in the general population, and many people with diabetes, drink alcoholic beverages. Alcohol may have both untoward and beneficial effects. Many ecological, case control and cohort studies based on people who do not have diabetes suggest that moderate intake of a range of alcoholic drinks is linked to reduced risk of coronary heart disease [222 (IIb)] and stroke [223 (III)]. A limited amount of information based on four studies in individuals with T2DM confirms this association. The benefit appears to be principally derived from the alcohol rather than other components of the various types of beverages [224 (III)]. Moderate intakes of alcohol may confer benefit by elevating levels of high density lipoprotein, reducing coagulability and decreasing lipid oxidation through antioxidant nutrients. Regular but moderate consumption of alcohol (at least 3 to 4 days/week) has a more beneficial effect than drinking occasionally higher quantities [225 (III)]. Neither the timing of alcohol intake in relation to meals nor the type of beverage consumed alters the expected benefits [225 (III), 226 (IIb)].

Alcohol may be an important energy source to an extent that is relevant in those who are overweight. Furthermore a high alcohol consumption is associated with a greater waist-hip ratio independently of body mass index [227 (III)]. On the other hand, moderate amounts of alcohol might be associated with improved insulin sensitivity [228 (Ib), 229 (IIb), 230 (III)]. Alcohol can also be associated with raised levels of blood pressure, increased triglycerides and an increased risk of hypoglycaemia [231, 232 (III)]. There are no conclusive data regarding an appropriate upper limit of alcohol intake for people with diabetes. Thus the recommendation is

based upon that suggested for the general population (233).

Abstention from alcohol should be advised for women during pregnancy and those with a history of pancreatitis or alcohol abuse, appreciable hypertriglyceridaemia, advanced neuropathy and erectile dysfunction. Recommendations regarding alcohol for people with diabetes must therefore depend upon the characteristics of the individual patient, and the socioeconomic consequences of overconsumption should not be forgotten. There is insufficient information to encourage patients who do not drink alcohol to start.

The recommendation regarding the need to consume carbohydrate when alcohol is taken is made because of the potential serious consequences of severe alcohol-induced hypoglycaemia. While a modest amount of alcohol can usually be taken without directly causing hypoglycaemia, the risk increases with the quantity consumed [3 (IV)].

Prevention of diabetes

Recommendations
– Avoidance of overweight and regular physical activity provide a means of reducing the risk of developing T2DM. Grade A
– Weight reduction and maintenance of weight loss in overweight individuals is a critical component of the lifestyle modification programme which may be expected to reduce the risk of developing T2DM. Grade A
– Appropriate macronutrient composition for diets aimed at reducing risk of T2DM is as follows: total fat intake <30% energy intake, saturated fat intake <10% energy intake, fibre intake >15 g/1000 kcal. Grade A

Commentary
An impressive series of longitudinal studies show a reduced risk of T2DM in those who are not overweight, have a high intake of dietary fibre (especially cereal fibre) and low GI foods or consume relatively little saturated fat and partake of regular activity [85, 234-243 (III)]. A high consumption of sugar sweetened beverages has been associated with weight gain and an increased risk of T2DM in women [244 (III)]. A well-designed randomised controlled study has demonstrated enhanced insulin sensitivity when saturated fatty acids are replaced by unsaturated vegetable oils in the context of a diet containing moderate amounts of total fat, *ie* less than 37% total energy [66 (Ib)]. Three randomised controlled trials conducted in China, Finland and the United States in individuals with impaired glucose tolerance (IGT) have shown a nearly 60% reduction of progres-

sion from IGT to T2DM over an approximately 3 $\frac{1}{2}$ year period in association with modest weight loss [245, 6, 7 (Ib)]. The benefit appears to have been sustained in the Finnish study [246 (Ib)]. In two of the three studies (6,7) weight loss was achieved by a combination of diet and exercise, the recommended diet being reduced in total and saturated fat and high in dietary fibre. In the third (245) randomisation was to clinics where participants received advice to increase level of activity, to modify their diet, to alter both diet and exercise, or no specific lifestyle advice. Comparable benefit was seen in each of the intervention groups. The benefit appears to be principally explained by weight loss and physical activity [247 (IB)]. Thus for those who are overweight or obese, especially if there is a strong family history of T2DM or if they have impaired glucose metabolism, weight loss should be strongly encouraged. A BMI within the recommended range is the goal for those who are overweight or obese, but a more practical approach, and the one used in the Finnish Study, is to advise a weight reduction of 5-7% of initial body weight or a weight loss of 5-10 kg depending upon degree of obesity. In both the Finnish and US intervention studies frequent ingestion of wholegrain products, vegetables, fruit, low fat milk and meat products, soft margarines and vegetable oils rich in MUFA were the means of facilitating the appropriate macronutrient composition. In addition the traditional Mediterranean diet and other traditional dietary patterns may be equally appropriate. Physical activity of at least moderate intensity (eg brisk walking) for at least 30 minutes per day is an important component of lifestyle modification aimed at reducing risk of T2DM and together with an increase in dietary fibre has been shown to make a contribution to risk reduction which is independent of weight loss. A similar exercise and dietary regimen has been shown to improve insulin sensitivity in insulin resistant individuals prior to the development of impaired glucose tolerance (248). There is currently no published evidence that weight loss achieved by diets high in fat or protein and low in carbohydrate will achieve similar results in those with insulin resistance or impaired glucose tolerance.

Regular vitamin D supplementation or a high dietary intake among young children has been shown to be associated with a lower risk of T1DM [249 (III)]. Three prospective studies have shown a consistent inverse association between magnesium intake and fasting insulin levels as well as risk of developing T2DM (250-253). Low magnesium levels have also been linked to other features of the metabolic syndrome in non-diabetic individuals (254). A high intake of magnesium in drinking water (>2.61 mg/l) appears to be protective against the development of T1DM in childhood

(255). A negative association has been reported between coffee consumption and risk of T2DM (256-260). However the absence of clinical trials precludes definitive recommendations regarding the roles of vitamin D or magnesium in the prevention of diabetes at present. Clinical trials have not confirmed an earlier suggested beneficial effect of nicotinamide in the prevention of T1DM (261).

Supplements and functional foods

– No recommendations are offered regarding supplements and functional foods. A number of such products is now available.

Commentary

Many functional foods and supplements are currently being promoted as beneficial for the management of people with diabetes or for reducing the risk of developing diabetes and its complications. These include fibre-enriched products and margarines containing plant sterols or stanols, and supplements containing various dietary fibres, n-3 fatty acids, minerals, trace elements and some herbs. Many of these products have been shown to have potentially relevant functional effects but have not been tested in long term clinical trials. The DNSG considers that, in the light of current evidence, the principal benefits of nutritional approaches to the treatment and prevention of diabetes are derived from the appropriate intake of usual foods. Because functional foods and supplements have not been a component of any traditional dietary pattern the Group believes that longer term evaluation in formal clinical trials is required before offering firm recommendations.

Acknowledgements

References

1. Mann J, Toeller M, Riccardi G, *et al* on behalf of the Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes (1988) Statement: Nutritional recommendations for individuals with diabetes mellitus. Diab Nutr Metab 1: 145-149

2. Slama G, Lean M, Mann J, *et al* on behalf of the Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) (1995) Recommendations for the nutritional management of patients with diabetes mellitus. Diab Nutr Metab 8: 186-189

3. Mann J, Lean M, Toeller M, Slama G, Uusitupa M, Vessby B on behalf of the Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) (2000) Recommendations for the nutritional management of patients with diabetes mellitus. Eur J Clin Nutr 54: 353-355.

4. Scottish Intercollegiate Guidelines Network (1999) SIGN Guidelines. An introduction to SIGN methodology for the development of evidence-based clinical guidelines. 1999, www.show.scot.nhs.uk/sign/home.htm

5. Moore H, Summerbell C, Hooper L, *et al* (2004) Dietary advice for treatment of type 2 diabetes mellitus in adults (Cochrane Review) In: The Cochrane Library, Issue 3, John Wiley & Sons Ltd., Chichester, UK

6. Tuomilehto J, Lindström J, Eriksson JG, *et al* for the Finnish Diabetes Prevention Study Group (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350

7. Knowler WC, Barrett-Connor E, Fowler SE, *et al* for the Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403

8. Lew EA, Garfinkel L (1979) Variation in mortality by weight among 750,000 men and women. J Clin Dis 32: 563-567

9. Manson JE, Rimm EG, Stampfer MJ, *et al* (1991) Physical activity and incidence of non insulin dependent diabetes mellitus in women. Lancet 338: 774-778

10. Royal College of Physicians (1983) Obesity. J R Coll Physicians Lond 17: 1

11. European Association for the Study of Obesity: Guidelines for the management of obesity in adults (2002) European Project for Primary Care. www.iotf.org/oonet.easo

12. Hauner H, Hamann A, Husemann B, *et al* für die Deutsche Diabetes-Gesellschaft (DDG), Deutsche Adipositas-Gesellschaft (DAG) und Deutsche Gesellschaft für Ernährung (DGE) (2003) Evidenz-basierte Leitlinie. Prävention und Therapie der Adipositas. Diabetes und Stoffwechsel 12 (Suppl. 2): 35-46

13. Astrup A, Grunwald GK, Melanson EL, Saris WHM, Hill JO (2001) The role of low-fat diets in the body weight control: a meta-analysis of ad libitum dietary intervention studies. Int J Obes 24: 1545-1552

14. Eriksson KF, Lindgarde F (1991) Prevention of type 2 (non insulin dependent) diabetes mellitus by diet and physical exercise. Diabetologia 34: 891-898

15. Goldstein DJ (1992) Beneficial health effects of modest weight loss. Int J Obes 16: 397-415

16. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH (1990) Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 7: 228-233

17. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C (1995) Prospective study of intentional weight loss and mortal-

ity in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 141: 1128-1141

18. Perri M, Sears SJ, Clark J (1993) Strategies for improving maintenance of weight loss. Towards a continuous care model of obesity management. Diabetes Care 16: 200-209

19. Anderson JW, Konz EC, Frederich RC, Wood CL (2002) Long-term weight loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 74: 579-584

20. Van Gaal L, Rillaerts E, Creten W, De Leeuw I (1988) Relationship of body fat distribution pattern to atherogenic risk factors in NIDDM. Diabetes Care 11: 103-106

21. Lean MEJ, Han TS, Morrison CE (1995) Waist circumference as a measure for indicating need for weight management. Br Med J 311: 158-161

22. Scottish Intercollegiate Guidelines Network (2003) Guidelines No. 69: Obesity in children and young people. SIGN. www.show.scot.nhs.uk/guidelines/fulltext/69.html

23. WHO (2003) Technical Report Series 916. Diet, nutrition and the prevention of chronic diseases. Report of a Joint FAO/WHO Expert Consultation. World Health Organisation, Geneva

24. Brage S, Wedderkopp N, Ekelund U, et al the European Youth Heart Study (EYHS) (2004) Features of the metabolic syndrome are associated with objectively measured physical activity and fitness in Danish children. Diabetes Care 27: 2141-2148

25. St-Onge MP, Janssen I, Heymsfield SB (2004) Metabolic syndrome in normal-weight Americans. Diabetes Care 27: 2222-2228

26. Humphreys M, Cronin CC, Barry DG, Ferriss JB (1994) Are the nutritional recommendations for insulin-dependent diabetic patients being achieved? Diabet Med 11: 79-84

27. Eeley EA, Stratton IM, Hadden DR, Turner RC, Holman RR (1996) UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group. Diabet Med 13: 656-662

28. Toeller M, Klischan A, Heitkamp G, et al and the EURODIAB IDDM Complications Study Group (1996) Nutritional intake of 2868 IDDM patients from 30 centres in Europe. Diabetologia 39: 929-939

29. Thanopoulou A, Karamanos B, Angelico F, et al (2004) Nutritional habits of subjects with type 2 diabetes mellitus in the Mediterranean Basin: comparison with the non-diabetic population and the dietary recommendations. Multi-Centre Study of the Mediterranean Group for the Study of Diabetes (MGSD). Diabetologia 47: 367-376

30. Watts GF, Gregory L, Naoumova R, Kubal C, Shaw KM (1988) Nutrient intake in insulin-dependent diabetic patients with incipient nephropathy. Eur J Clin Nutr 42: 697-702

31. Kalk WJ, Osler C, Constable J, Kruger M, Panz V (1992) Influence of dietary protein on glomerular filtration and urinary albumin excretion in insulin-dependent diabetes. Am J Clin Nutr 56: 169-173

32. Riley MD, Dwyer T (1998) Microalbuminuria is positively associated with usual dietary saturated fat intake and negatively associated with usual dietary protein intake in people with insulin-dependent diabetes mellitus. Am J Clin Nutr 67: 50-57

33. O'Hayon BE, Cummings EA, Daneman D, Ossip MG, Lawson ML, Sochett EB (2000) Does dietary protein intake correlate with markers suggestive of early diabetic nephropathy in children and adolescents with type 1 diabetes mellitus? Diabet Med 17: 708-712

34. Toeller M, Buyken A, Heitkamp G, et al and the EURODIAB IDDM Complications Study Group (1997) Protein intake and urinary albumin excretion rates in the EURODIAB IDDM Complications Study. Diabetologia 40: 1219-1226

35. Nyberg G, Norden G, Attman PO, et al (1987) Diabetic nephropathy: is dietary protein harmful? J Diabetes Complications 1: 37-40

36. Bouhanick B, Suraniti S, Berrut G, et al (1995) Relationship between fat intake and glomerular filtration rate in normotensive insulin-dependent diabetic patients. Diabet Med 21: 168-172

37. Jameel N, Pugh JA, Mitchell BD, Stern MP (1992) Dietary protein intake is not correlated with clinical proteinuria in NIDDM. Diabetes Care 15: 178-183

38. Pijls LT, de Vries H, Kriegsman DM, Donker AJ, van Eijk JT (2001) Determinants of albuminuria in people with type 2 diabetes mellitus. Diabetes Res Clin Pract 52: 133-143

39. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH (1996) The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 124: 627-632

40. Ciavarella A, Di Mizio G, Stefoni S, Borgnino LC, Vannini P (1987) Reduced albuminuria after dietary protein restriction in insulin-dependent diabetic patients with clinical nephropathy. Diabetes Care 10: 407-413

41. Bending JJ, Dodds RA, Keen H, Viberti GC (1988) Renal response to restricted protein intake in diabetic nephropathy. Diabetes 37: 1641-1646

42. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR (1991) Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324: 78-84

43. Raal FJ, Kalk WJ, Lawson M, et al (1994) Effect of moderate dietary protein restriction on the progression of overt diabetic nephropathy: a 6-mo prospective study. Am J Clin Nutr 60: 579-585

44. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH (2002) Effect of dietary protein restriction prognosis in patients with diabetic nephropathy. Kidney Int 62: 220-228

45. Nair KS, Garrow JS, Ford C, Mahler RF, Halliday D (1983) Effect of poor diabetic control and obesity on whole body protein metabolism in man. Diabetologia 25: 400-403

46. Gougeon R, Pencharz PB, Marliss EB (1994) Effect of NIDDM on the kinetics of whole-body protein metabolism. Diabetes 43: 318-328

47. Gougeon R, Pencharz PB, Sigal RJ (1997) Effect of glycemic control on the kinetics of whole-body protein metabolism in obese subjects with non-insulin-dependent diabetes mellitus during iso- and hypoenergetic feeding. Am J Clin Nutr 65: 861-870

48. Gougeon R, Marliss EB, Jones PJ, Pencharz PB, Morais JA (1998) Effect of exogenous insulin on protein metabolism with differing nonprotein energy intakes in type 2 diabetes mellitus. Int J Obes 22: 250-261

49. Cohen D, Dodds R, Viberti G (1987) Effect of protein restriction in insulin dependent diabetics at risk of nephropathy. Br Med J 294: 795-798

50. Dullaart RP, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ (1993) Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 16: 483-492

51. Holler C, Abrahamian H, Auinger M (1999) Effect of nutrition on microalbuminuria in patients with type 1 diabetes: prospective data evaluation over 5 years. Acta Med Austriaca 26: 168-172

52. Rudberg S, Dahlquist G, Aperia A, Persson B (1988) Reduction of protein intake decreases glomerular filtration rate in young type 1 (insulin-dependent) diabetic patients mainly in hyperfiltering patients. Diabetologia 31: 878-883

53. Pedersen MM, Mogensen CE, Jorgensen FS, Moller B, Lykke G, Pedersen O (1989) Renal effects from limitation of high dietary protein in normoalbuminuric diabetic patients. Kidney Int 27 (Suppl): S115-S121

54. Pijls LT, de Vries H, Donker AJ, van Eijk JT (1999) The effect of protein restriction on albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Nephrol Dial Transplant 14: 1445-1453

55. Meloni C, Morosetti M, Suraci C, et al (2002) Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr 12: 96-101

56. Pomerleau J, Verdy M, Garrel DR, Nadeau MH (1993) Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36: 829-834

57. Kontessis PA, Bossinakou I, Sarika L, et al (1995) Renal, metabolic and hormonal responses to proteins of different origin in normotensive, nonproteinuric type 1 diabetic patients. Diabetes Care 18: 1233

58. Jibani MM, Bloodworth LL, Foden E, Griffiths KD, Galpin OP (1991) Predominantly vegetarian diet in patients with incipient and early clinical diabetic nephropathy: effects on albumin excretion rate and nutritional status. Diabet Med 8: 949-953

59. Wheeler ML, Fineberg SE, Fineberg NS, Gibson RG, Hackward LL (2002) Animal versus plant protein meals in individuals with type 2 diabetes and microalbuminuria: effects on renal, glycemic, and lipid parameters. Diabetes Care 25: 1277-1282

60. Teixeira SR, Tappenden KA, Carson L, et al (2004) Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 diabetes mellitus and nephropathy. J Nutr 134: 1874-1880

61. Anderson JW, Blake JE, Turner J, Smith BM (1998) Effect of soy protein on renal function and proteinuria in patients with type 2 diabetes. Am J Clin Nutr 68(suppl): S1347-S1353

62. Mollsten AV, Dahlquist GG, Stattin EL, Rudberg S (2001) Higher intakes of fish protein are related to a lower risk of microalbuminuria in Swedish type 1 diabetic patients. Diabetes Care 24: 805-810

63. Pecis M, de Azevedo MJ, Gross JL (1994) Chicken and fish diet reduces glomerular hyperfiltration in IDDM patients. Diabetes Care 17: 665-672

64. Gross JL, Zelmanovitz T, Moulin CC, et al (2002) Effect of a chicken-based diet on renal function and lipid profile in patients with type 2 diabetes: a randomized crossover trial. Diabetes Care 25: 645-651

65. Astrup A, Ryan L, Grunwald GK, et al (2000) The role of dietary fat in body fatness: evidence from a preliminary meta-analysis of ad libitum low-fat dietary intervention studies. Br J Nutr 83 (Suppl. 1): S25-S32

66. Vessby B, Uusitupa M, Hermansen K, et al (2001) Substituting dietary saturated fat with monounsaturated fat impairs insulin sensitivity in healthy men and women: the KANWU Study. Diabetologia 44: 312-319

67. Katan MB, Zock PL, Mensink MP (1995) Dietary oils, serum lipoproteins, and coronary heart disease. Am J Clin Nutr 61: 1368S-1373S

68. Howell WH, McNamara DJ, Tosca MA, Smith BT, Gaines JA (1997) Plasma lipid and lipoprotein responses to dietary fat and cholesterol: meta analysis. Am J Clin Nutr 65: 1747-1764

69. Mensink RP, Zock PL, Kester ADM, Katan MB (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL-cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 77: 1146-1155

70. Heine RJ, Mulder C, Popp-Snijders C, van der Meer J, van der Veen EA (1989) Linoleic-acid-enriched diet: long term effects on serum lipoprotein and apolipoprotein concentrations and insulin sensitivity in non-insulin dependent diabetic patients Am J Clin Nutr 49: 448-456

71. Vessby B, Gustafsson I-B, Boberg J, Karlström B, Lithell H, Werner I (1980) Substituting polyunsaturated for saturated fat as a single change in a Swedish diet: effects on serum lipoprotein metabolism and glucose tolerance in patients with hyperlipoproteinaemia. Eur J Clin Invest 10: 193-202

72. Pérez-Jiménez F, López-Miranda J, Pinillos MD, et al (2001) A Mediterranian and a high-carbohydrate diet improve glucose metabolism in healthy young persons. Diabetologia 44: 2038-2043

73. Summers LKM, Fielding BA, Bradshaw HA, et al (2002) Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia 45: 369-377

74. Storm H, Thomsen C, Pedersen E, Rasmussen O, Christiansen C, Hermansen K (1997) Comparison of a carbohydrate-rich diet and diets rich in stearic or palmitic acid in NIDDM patients. Diabetes Care 20: 1807-1814

75. Cox C, Mann J, Sutherland W, Chisholm A, Skeaff M (1995) Effects of coconut oil, butter, and safflower oil on lipids and lipoproteins in persons with moderately elevated cholesterol levels. J Lipid Res 36: 1501-1510

76. Thomsen C, Rasmussen O, Lousen T, et al (1999) Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects. Am J Clin Nutr 69: 1135-1143

77. Thomsen C, Storm H, Holst JJ, Hermansen K (2003) Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 response in patients with type 2 diabetes. Am J Clin Nutr 77: 605-611

78. Christiansen E, Schnider S, Palmvig B, Tauber-Lassen E, Pedersen O (1997) Intake of a diet high in trans monounsaturated fatty acids or saturated fatty acids. Effects on postprandial insulinemia and glycemia in obese patients with NIDDM. Diabetes Care 20: 881-887

79. Soinio M, Laakso M, Lehto S, Hakala P, Ronnemaa T (2003) Dietary fat predicts coronary heart disease events in subjects with type 2 diabetes. Diabetes Care 26: 619-624

80. Tanasescu M, Cho E, Manson JE, Hu FB (2004) Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr 79: 999-1005

81. Vessby B, Aro A, Skarfors E, Berglund L, Salminen I, Lithell H (1994) The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters. Diabetes 43: 1353-1357

82. Laaksonen DE, Lakka TA, Lakka H-M, et al (2002) Serum fatty acid composition predicts development of impaired fasting glycaemia and diabetes in middle-aged men. Diabetic Med 19: 456-464

83. Wang L, Folsom AR, Zheng Z, Pankow JS, Eckfeldt JH, ARIC Study Investigators (2003) Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 78: 91-98

84. Feskens EJM (2001) Can diabetes be prevented by vegetable fat? Diabetes Care 24: 1517-1518

85. Hu FB, van Dam RM, Liu S (2002) Diet and risk of type 2 diabetes: the role of types of fat and carbohydrate. Diabetologia 44: 805-817

86. Meyer KA, Kushi LH, Jacobs DR, Folsom AR (2001) Dietary fat and incidence of type 2 diabetes in older Iowa women. Diabetes Care 24: 1528-1535

87. Salméron J, Hu FB, Manson JA, et al (2001) Dietary fat intake and the risk of type 2 diabetes in women. Am J Clin Nutr 73: 1019-1026

88. Marshall JA, Bessesen DH (2002) Dietary fat and the development of type 2 diabetes. Diabetes Care 25: 620-622

89. Van Dam R, Willet W, Rimm EK, Stampfer MJ, Hu FB (2002) Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 25: 417-424

90. Katan MB, Zock PL, Mensink RP (1995) Trans fatty acids and their effects on lipoproteins in humans. Ann Rev Nutr 15: 473-493

91. Garg A (1998) High-monounsaturated fat diets for patients with diabetes mellitus: a meta-analysis. Am J Clin Nutr 67 (suppl.): 577S-582S

92. Bonanome A, Visona A, Lusiani L, et al (1991) Carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus: effects of a low-fat, high carbohydrate diet vs a diet high in monounsaturated fatty acids. Am J Clin Nutr 54: 586-590

93. Luscombe ND, Noakes M, Clifton PM (1999) Diets high and low in glycemic index versus high monounsaturated fat diets: effects on glucose and lipid metabolism in NIDDM. Eur J Clin Nutr 53: 473-478

94. Thomsen C, Rasmussen O, Christiansen C, et al (1999) Comparison of the effects of a monounsaturated fat diet and a high carbohydrate diet on cardiovascular risk factors in first degree relatives to type-2 diabetes. Eur J Clin Nutr 53: 818-823

95. Rodrigues-Villar C, Manzaneres JM, Casals E, et al (2000) High-monounsaturated fat, olive oil-rich diet has effects similar to a high-carbohydrate diet on fasting and postprandial state and metabolic profiles of patients with type 2 diabetes. Metabolism 49: 1511-1517

96. Toeller M, Buyken AE, Heitkamp G, Cathelineau G, Ferriss JB, Michel G, and the EURODIAB IDDM Complications Study Group (2001) Nutrient intakes as predictors of body weight in European people with type 1 diabetes. Int J Obes 25: 1815-1822

97. Poppitt SD, Keogh GF, Prentice AM, et al (2002) Long term effects of ad libitum low-fat high-carbohydrate diets on body weight and serum lipids in overweight subjects with metabolic syndrome. Am J Clin Nutr 75: 11-20

98. Swinburn BA, Metcalf PA, Ley SJ (2001) Long-term (5-year) effects of a reduced-fat diet intervention in individuals with glucose intolerance. Diabetes Care 24: 619-624

99. Thomsen C, Rasmussen OW, Hansen KW, Vesterlund M, Hermansen K (1995) Comparison of the effects on the diurnal blood pressure, glucose, and lipid levels of a diet rich in monounsaturated fatty acids with a diet rich in polyunsaturated fatty acids in type 2 diabetic subjects. Diabet Med 12: 600-606

100. Rasmussen OW, Thomsen C, Hansen KW, Versterlund M, Winther E, Hermansen K (1993) Effects on blood pressure, glucose, and lipid levels of a high-monounsaturated fat diet compared with a high-carbohydrate diet in NIDDM subjects. Diabetes Care 16: 1565-1571

101. Katsilambros N, Kostalas G, Michalakakis N, et al (1996) Metabolic effects of long-term diets enriched in olive oil or sunflower oil in non-insulin-dependent diabetes. Nutr Metab Cardiovasc Dis 6: 164-167

102. Toeller M, Buyken AE, Heitkamp G, Berg G, Scherbaum WA and the EURODIAB IDDM Complications Study Group (1999)

Prevalence of chronic complications, metabolic control and nutritional intake in type 1 diabetes: Comparison between different European regions. Horm Metab Res 31: 680-685

103. Hu FB (2001) The role of n-3 polyunsaturated fatty acids in the prevention and treatment of cardiovascular disease. Drugs Today 37: 49-56

104. Harris WS, Park Y, Isley WL (2003) Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol 14: 9-14

105. Farmer A, Montori V, Dinneen S, Clar C (2001) Fish oil in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. CD003205. (metaanalys, lipider. TG ner, LDL chol upp)

106. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE (1998) Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 21: 494-500

107. Montori VM, Farmer A, Wollan PC, Dinneen SF (2000) Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 23: 1407-1415

108. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE (2003) Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and mortality in diabetic women. Circulation 107: 1852-1857

109. Weggemans RM, Zock PL, Katan MB (2001) Dietary cholesterol from eggs increases the ratio of total cholesterol to high-density lipoprotein cholesterol in humans: a meta-analysis. Am J Clin Nutr 73: 885-891

110. Romano G, Tilly-Kiesi MK, Patti L, et al (1998) Effects of dietary cholesterol on plasma lipoproteins and their subclasses in IDDM patients. Diabetologia 41: 193-200

111. Toeller M, Buyken A, Heitkamp G, Scherbaum WA, Krans HMJ, Fuller JH and the EURODIAB IDDM Complications Study Group (1999) Associations of fat and cholesterol intake with serum lipid levels and cardiovascular disease: The EURODIAB IDDM Complications Study. Exp Clin Endocrinol Diabetes 107: 512-521

112. Riccardi G, Rivellese AA (2000) Dietary treatment of the metabolic syndrome: the optimal diet. Br J Nutr 83 (Suppl.1): 143-148

113. Toeller M, Mann JI (2003) Nutrition in the etiology and management of type 2 diabetes. In: Goldstein BJ, Müller-Wieland D (Eds), Textbook of type 2 diabetes. Martin Dunitz, London, New York, pp 51-63

114. Garg A, Bonanome A, Grundy SM, Zhang ZJ, Unger RH (1988) Comparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 319: 829-834

115. Rivellese AA, Giacco R, Genovese S, et al (1990) Effects of changing amount of carbohydrate in diet on plasma lipoproteins and apolipoproteins in type II diabetic patients. Diabetes Care 13: 446-448

116. Garg A, Grundy SM, Unger RH (1992) Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes 41: 1278-1285

117. Parillo M, Rivellese AA, Ciardullo AV, et al (1992) A high-monounsaturated fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetes patients. Metabolism 41: 1373-1378

118. Campbell LV, Marmot PE, Dyer JA, Borkman M, Storlien LH (1994) The high-monounsaturated fat diet as a practical alternative for NIDDM. Diabetes Care 17: 177-188

119. Garg A, Bantle JP, Henry RR, et al (1994) Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 271: 1421-1428

120. Lerman-Garber I, Ichazo-Cerro S, Zamora-Gonzalez J, Cardoso-Saldana G, Posadas-Romero C (1994) Effect of a high-monounsaturated fat diet enriched with avocado in NIDDM patients. Diabetes Care 17: 311-315

121. Parillo M, Giacco R, Ciardullo AV, Rivellese AA, Riccardi G (1996) Does a high-carbohydrate diet have different effects in NIDDM patients treated with diet alone or hypoglycaemic drugs? Diabetes Care 19: 498-500

122. Gerhard GT, Ahmann A, Meeuws K, McMurry MP, Barton Duell P, Conner WE (2004) Effects of a low-fat diet compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins and glycaemic control in type 2 diabetes. Am J Clin Nutr 80: 668-673

123. Georgopoulos A, Bantle JP, Noutsou M, Swaim WR, Parker SJ (1998) Differences in the metabolism of postprandial lipoproteins after a high-monounsaturated fat versus a high-carbohydrate diet in patients with type 1 diabetes mellitus. Arterioscler Thromb Vasc Biol 18: 773-782

124. Buyken AE, Toeller M, Heitkamp G, et al and the EURODIAB IDDM Complications Study Group (2000) Carbohydrate sources and glycaemic control in type 1 diabetes mellitus. Diabet Med 17: 351-359

125. Strychar I, Ishac A, Rivard M, et al (2003) Impact of a high-monounsaturated fat diet on lipid profile in subjects with type 1 diabetes. J Am Diet Assoc 103: 467-474

126. Shah M, Garg A (1996) High fat and high carbohydrate diets and energy balance: a review. Diabetes Care 19: 1142-1152

127. Foster GD, Wyatt HR, Hill JO, et al (2003) A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348: 2082-2090

128. Samaha FF, Iqbal N, Sheshadri P, et al (2003) A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 348: 2074-2081

129. Toeller M, Buyken A (1998) Protein intake - new evidence for its role in diabetic nephropathy. Editorial comment. Nephrol Dial Transplant 13: 1926-1927

130. Karamanos B, Thanopoulou A, Angelico F, et al (2002) Nutritional habits in the Mediterranean Basin: The macronutrient composition of diet and its relation with the traditional Mediterranean diet. Multi-centre study of the Mediterranean Group for the Study of Diabetes (MGSD). Eur J Clin Nutr 56: 983-991

131. Buyken A, Toeller M, Heitkamp G, *et al* and the EURODIAB IDDM Complications Study Group (1998) Relation of fibre intake to HbA1c and the prevalence of severe ketoacidosis and severe hypoglycaemia. Diabetologia 41: 882-890

132. Buyken AE, Toeller M, Heitkamp G, *et al* and the EURODIAB IDDM Complications Study Group (2001) Glycemic index in the diet of European outpatients with type 1 diabetes: relations to HbA1c and serum lipids. Am J Clin Nutr 73: 574-581

133. Mann J, Hermansen K, Vessby B, Toeller M (2002) Evidence-based nutritional recommendations for the treatment and prevention of diabetes and related complications. A European perspective (letter). Diabetes Care 25: 1256-1258

134. Toeller M (2002) Fibre consumption, metabolic effects and prevention of complications in diabetic patients: epidemiological evidence. Digest Liver Dis 34: S145-S149

135. European Diabetes Policy Group (1998) A desktop guide to type 1 (insulin dependent) diabetes mellitus. Exp Clin Endocrinol Diabetes 106: 240-269

136. European Diabetes Policy Group (1999) A desktop guide to type 2 diabetes mellitus. Diabetic Med 16: 716-730

137. Chantelau EA, Frenzen A, Gösseringer G, Hansen I, Berger M (1987) Intensive insulin therapy justifies simplification of the diabetes diet: a prospective study in insulin-dependent diabetic patients. Am J Clin Nutr 45: 958-962

138. Toeller M (1993) Diet and diabetes. Diabetes Metab Rev 9: 93-108

139. Wolever TM, Hamad S, Chiasson JL, *et al* (1999) Day-to-day consistency in amount and source of carbohydrate associated with improved blood glucose control in type 1 diabetes. J Am Coll Nutr 18: 242-247

140. Daly ME, Vale C, Walker M, Alberti KG, Mathers JC (1997) Dietary carbohydrates and insulin sensitivity: a review of the evidence and clinical implications. Am J Clin Nutr 66: 1072-1085

141. Wolever TM, Mehling C (2003) Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr 77: 612-621

142. Joshipura KJ, Hu FB, Manson JE, *et al* (2001) The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med 134: 1106-1114

143. Sargeant LA, Khaw KT, Bingham S, *et al* (2001) Fruit and vegetable intake and population glycosylated haemoglobin levels: the EPIC-Norfolk Study. Eur J Clin Invest 55: 342-348

144. Rivellese A, Riccardi G, Giacco A, *et al* (1980) Effect of dietary fibre on glucose control and serum lipoproteins in diabetic patients. Lancet 2: 447-450

145. Riccardi G, Rivellese A, Pacioni D, Genovese S, Mastranzo P, Mancini M (1984) Separate influence of dietary carbohydrate and fibre on the metabolic control in diabetes. Diabetologia 26: 116-121

146. Simpson HCR, Simpson RW, Lousley S, *et al* (1981) A high carbohydrate leguminous fibre diet improves all aspect of diabetic control. Lancet 1: 1-5

147. Lousely SE, Jones DB, Slaughter P, Carter RD, Jelfs R, Mann JI (1984) High carbhydrate- high fibre diets in poorly controlled diabetes. Diabet Med 1: 21-25

148. Simpson RW, Mann J, Eaton J, Carter RD, Hockaday TDR (1979) High-carbohydrate diets and insulin dependent diabetics. Br Med J 2: 523-525

149. Simpson HCR, Carter RD, Lousley S, Mann JL (1982) Digestible carbohydrate – an independent effect on diabetic control in type II (non-insulin dependent) diabetic patients? Diabetologia 23: 235-239

150. Perrotti N, Santoro D, Genovese S, Giacco A, Rivellese A, Riccardi G (1984) Effect of digestible carbohydrates on glucose control in insulin dependent patients with diabetes. Diabetes Care 7: 354-359

151. Mann J (1984) Lines to legumes: changing concepts of diabetic diets. Diabetic Med 1: 191-198

152. Mann J (2001) Dietary fibre and diabetes revisited. Eur J Clin Nutr 55: 919-921

153. Giacco R, Parillo M, Rivellese AA, *et al* (2000) Long-term dietary treatment with increased amounts of fiber-rich low-glycemic index natural foods improves blood glucose control and reduces the number of hypoglycemic events in type 1 diabetic patients. Diabetes Care 23: 1461-1466

154. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ (2000) Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 342: 1392-1398

155. Hollenbeck CB, Coulston AM, Reaven GM (1986) To what extent does increased dietary fiber improve glucose and lipid metabolism in patients with non insulin-dependent diabetes mellitus (NIDDM)? Am J Clin Nutr 6: 16-24

156. Toeller M, Buyken AE, Heitkamp G, de Pergola G, Giorgino F, Fuller JH (1999) Fiber intake, serum cholesterol levels, and cardiovascular disease in European individuals with type 1 diabetes. EURODIAB IDDM Complications Study Group. Diabetes Care 22 (suppl.2): B21-B28

157. Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willet WC (1996) Vegetable, fruit and cereal fiber intake and risk of coronary heart disease among men. JAMA 275: 447-451

158. Bazzano LA, He J, Ogden LG, Loira CM, Whelton PK. National Health and Nutrition Survey I Epidemiological Follow-up Study (2003) Dietary fiber intake and reduced risk of coronary heart disease in US men and women: The National Health and Nutrition Survey I Epidemiological Follow-up Study. Arch Intern Med 163: 1897-1904

159. Wu H, Dwyer KM, Fan Z, Shircore A, Fan J, Dwyer JH (2003) Dietary fiber and progression of atherosclerosis: the Los Angeles Atherosclerosis Study. Am J Clin Nutr 78: 1085-1091

160. Pereira MA, O'Reilly E, Augustsson K, *et al* (2004) Dietary fiber and risk of coronary heart disease: a pooled analysis of cohort studies. Arch Intern Med 164: 370-376

161. Appleby PN, Thorogood M, Mann JI, Key TJ (1998) Low body mass index in non-meat eaters: the possible roles of animal fat, dietary fibre and alcohol. Int J Obes 22: 454-460

162. McKeown NM, Meig SJB, Liu S, Saltzman E, Wilson PWF, Jacques PF (2004) Carbohydrate nutrition, insulin resistance, and the prevalence of the Metabolic Syndrome in the Framingham Offspring Cohort. Diabetes Care 27: 538-546

163. Venn BJ, Mann JI (2004) Cereal grains, legumes and diabetes. Eur J Clin Nutr 58 : 1443-1461

164. Willett WC, Manson J, Liu S (2002) Glycemic index, glycemic load, and risk of type 2 diabetes. Am J Clin Nutr 76: 274S-280S

165. Franz MJ (2003) Meta-analysis of low-glycemic index diets in the management of diabetes. (Letter) Diabetes Care 26: 3364-3365

166. Franz MJ (2003) The glycemic index: not the most effective nutrition therapy intervention (editorial). Diabetes Care 26: 2466-2468

167. Fontvieille AM, Acosta M, Rizkalla SW, et al (1988) A moderate switch from high to low glycaemic-index foods for 3 weeks improves the metabolic control of type 1 (IDDM) diabetic subjects. Diab Nutr Metab 1: 139-143

168. Brand J, Colagiuri S, Crossman S, Allen A, Roberts D, Truswell A (1991) Low-glycemic index foods improve long-term glycemic control in NIDDM. Diabetes Care 14: 95-101

169. Fontvieille A, Rizkalla S, Penformis A, Acosta M, Bornet F, Slama G (1992) The use of low glycaemic index foods improve metabolic control of diabetic patients over five weeks. Diabet Med 9: 444-450

170. Wolever T, Jenkins D, Vuksan V, et al (1992) Beneficial effect of a low glycaemic index diet in type 2 diabetes. Diabet Med 9: 451-458

171. Wolever T, Jenkins D, Vuksan V, Jenkins A, Wong G, Josse R (1992) Beneficial effect of a low-glycemic index diet in overweight NIDDM subjects. Diabetes Care 15: 562-564

172. Frost G, Wilding J, Beecham J (1994) Dietary advice based on the glycaemic index improves dietary profile and metabolic control in type 2 diabetic patients. Diabet Med 11: 397-401

173. Lafrance L, Rabasa-Lhoret R, Poisson D, Ducros F, Chiasson J (1998) Effects of different glycaemic index foods and dietary fibre intake on glycaemic control in type 1 diabetic patients on intensive insulin therapy. Diabet Med 15: 972-978

174. Järvi AE, Karlström BE, Granfeldt YE, Björck IME, Asp N-G, Vessby BOH (1999) Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low glycemic index diet in type 2 diabetes mellitus patients. Diabetes Care 22: 10-18

175. Gilbertson H, Brand-Miller J, Thorburn A, Evans S, Chondros P, Werther G (2001) The effect of flexible low glycemic index dietary advice versus measured carbohydrate exchange diets on glycemic control in children with type 1 diabetes. Diabetes Care 24: 1137-1143

176. Brand-Miller J, Hayne S, Petocz P, Colagiuri S (2003) Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 26: 2261-2267

177. Brand-Miller J, Petocz P, Colagiuri S (2003) Meta-analysis of low-glycemic index diets in the management of diabetes (letter). Diabetes Care 26: 3363

178. Mann J (2003) Meta-analysis of low-glycemic index diets in the management of diabetes (letter). Diabetes Care 26: 3364

179. Rizkalla SW, Taghrid L, Laromiguiere M, et al (2004) Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: A randomised-controlled trial. Diabetes Care 27: 1866-1872

180. Riccardi G, Clemente G, Giacco R (2003) Glycemic index of local foods and diets: the Mediterranean experience. Nutr Rev 61: S56-S60

181. Slama G, Haardt MJ, Jean-Joseph P, et al (1984) Sucrose taken during mixed meal has no additional hyperglycaemic action over isocaloric amounts of starch in well-controlled diabetics. Lancet 2: 122-125

182. Bornet F, Haardt MJ, Costagliola D, Blayo A, Slama G (1985) Sucrose or honey at breakfast have no additional acute hyperglycaemic effect over an isoglucidic amount of bread in type 2 diabetic patients. Diabetologia 28: 213-217

183. Peterson DB, Lambert J, Gerring S, et al (1986) Sucrose in the diet of diabetic patients-just another carbohydrate? Diabetologia 29: 216-220

184. Mann JI (1987) Simple sugars and diabetes. Diabet Med 4: 135-139

185. Mann J (2004) Free sugars and human health: sufficient evidence for action? Lancet 363: 1068-1070

186. Brynes A, Mark Edwards C, Ghatei M, et al (2003) A randomised four-intervention crossover study investigating the effect of carbohydrates on daytime profiles of insulin, glucose, non-esterified fatty acids and triacylglycerols in middle-aged men. Br J Nutr 89: 207-218

187. Raben A, Vasilaras T, Moller A, Astrup A (2002) Sucrose compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects. Am J Clin Nutr 76: 721-729

188. Bantle J, Raatz S, Thomas W, Georgopoulos A (2000) Effects of dietary fructose on plasma lipids in healthy subjects. Am J Clin Nutr 72: 1128-1134

189. Grigoresco C, Riskalla S, Halfon P, et al (1988) Lack of detectable deleterious effects on metabolic control of daily fructose ingestion for 2 months in NIDDM patients. Diabetes Care 11: 546-550

190. Fraser GE, Sabate J, Beeson WL, Strahan TM (1992) A possible protective effect of nut consumption on risk of coronary heart disease: the Adventist Health Study. Arch Intern Med 152: 1416-1424

191. Gaziano JM, Manson JE, Branch LG, Colditz GA, Willett WC, Buring JE (1995) A prospective study of consumption of carotenoids in fruits and vegetables and decreased cardiovascular mortality in the elderly. Ann Epidemiol 5: 255-260

192. Gillmann MW, Cupples LA, Gagnon D, et al (1995) Protective effect of fruits and vegetables on development of stroke in men. JAMA 273: 1113-1117

193. Hu FB, Stampfer MJ, Manson JE, *et al* (1998) Frequent nut consumption and risk of coronary heart disease in women: prospective cohort study. BMJ 317: 1341-1345

194. Joshipura KJ, Ascherio A, Manson JE, *et al* (1999) Fruit and vegetable intake in relation to risk for ischemic stroke. JAMA 282: 1233-1239

195. Liu S, Manson JE, Lee IM, *et al* (2000) Fruit and vegetable intake and risk of cardiovascular disease: the Women' Health Study. Am J Clin Nutr 72: 922-928

196. Joshipura KJ, HU FB, Manson JE, *et al* (2001) The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med 134: 1106-1114

197. Kris-Etherton PM, Zhao G, Binkoski AE, Coval SM, Etherton TD (2001) The effect of nuts on coronary heart disease risk. Nutr Rev 59: 103-111

198. Liu S, Lee IM, Ajani U, Cole SR, Buring JE, Manson JE (2001) Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: the Physicians' Health Study. Int J Epidemiol 30: 130-135

199. Albert CM, Gaziano JM, Willett WC, Manson JE (2002) Nut consumption and decreased risk of sudden cardiac death in the physicians' health study. Arch Intern Med 162: 1382-1387

200. Bazzano LA, He J, Ogden LG, *et al* (2002) Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr 76: 93-99

201. Jacobs DR, Meyer KA, Kushi LH, Folsom AR (1998) Wholegrain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women's Health Study. Am J Clin Nutr 68: 248-257

202. Liu S, Stampfer MJ, Hu FB, *et al* (1999) Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. Am J Clin Nutr 70: 412-419

203. Marckmann P, Groubaek M (1999) Fish consumption and coronary heart disease mortality: a systematic review of prospective cohort studies. Eur J Clin Nutr 53: 585-590

204. Oomen CM, Feskens EJM, Räsänen L, *et al* (2000) Fish consumption and coronary heart disease mortality in Finland, Italy, and the Netherlands. Am J Epidemiol 151: 999-1006

205. Ceriello A, Bortolotti N, Crescentini A, *et al* (1998) Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 28: 329-333

206. Rösen P, Toeller M (1999) Vitamin E in diabetes. Increase of oxidative stress and its prevention as a strategy to prevent vascular complications? Int J Vitam Nutr Res 69: 206-212

207. Upritchard JE, Sutherland WH, Mann JI (2000) Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 23: 733-738

208. Manning PJ, Sutherland WHF, Walker RJ, *et al* (2004) Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care 27: 2166-2171

209. Gaede P, Vedel P, Larsen N, Jensen GV, Parvig HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393

210. Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG (1989) Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ 289: 227-230

211. Ceriello A, Guigliano D, Quatraro A, Lefebvre PJ (1991) Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clin Sci 81: 739-742

212. Sacks FM, Svetkey LP, Vollmer WM, *et al* (2001) Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 344: 3-10

213. Appel LJ, Champagne CM, Harsha DW, *et al* Writing group of the PREMIER Collaborative Research Group (2003) Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 289: 2083-2093

214. McNair P, Christiansen MS, Christiansen C, Madsbad S, Transbol I (1982) Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis. Eur J Clin Invest 12: 81-85

215. Tosiello L (1996) Hypomagnesemia and diabetes mellitus: a review of clinical implications. Arch Intern Med 156: 1143-1148

216. De Block C, De Leeuw I (1999) Associated thyrogastric autoimmunity increases the prevalence of low erythrocyte magnesium in type 1 diabetes mellitus. Magn Res 12: 279-285

217. Sjogren A, Floren CH, Nilsson A (1986) Magnesium deficiency in IDDM related to level of glycosylated hemoglobin. Diabetes 35: 459-463

218. De Leeuw I, Vertommen J, Abs R (1978) The magnesium content of the trabecular bone in diabetic subjects. Biomedicine 29: 16-17

219. McNair P, Christiansen C, Madsbad S, *et al* (1978) Hypomagne-semia, a risk factor in diabetic retinopathy. Diabetes 27: 1075-1077

220. Engelen W, Bouten A, De Leeuw I, De Block C (2000) Are low magnesium levels in type 1 diabetes mellitus associated with electromyographical signs of polyneuropathy? Magn Res 13: 197-203

221. De Leeuw I, De Block C, Van Gaal L (2003) Long term Mg supplementation influences favourably the natural evolution of neuropathy and retinopathy in Mg depleted type 1 diabetic patients. Diabetologia 46: A396

222. Ajani UA, Gaziano JM, Lotufo PA, *et al* (2000) Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 102: 500-505

223. Sacco R, Elkind M, Boden-Albala B, *et al* (1999) The protective role of moderate alcohol consumption on ischemic stroke. JAMA 281: 51-60

224. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ (1996) Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine, or spirits? BMJ 312: 731-736

225. Mukamal KJ, Conigrave KM, Mittleman MA, *et al* (2003) Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 348: 109-118

226. Gaziano JM, Hennekens CH, Godfried SL, *et al* (1999) Type of alcoholic beverage and risk of myocardial infarction. Am J Cardiol 83: 52-57

227. Dallongeville J, Marecaux N, Ducimetiere P, *et al* (1998) Influence of alcohol consumption and various beverages on waist girth and waist-to-hip ratio in a sample of French men and women. Int J Obes 22: 1178-1183

228. Davies MJ, Baer DJ, Judd JT, Brown ED, Campbell WS, Taylor PR (2002) Effects of moderate alcohol intake on fasting insulin and glucose concentrations and insulin sensitivity in post-menopausal women. JAMA 287: 2559-2563

229. Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Campbell LV (2003) Moderate alcohol consumption, estrogen replacement therapy, and physical activity are associated with increased insulin sensitivity: is abdominal adiposity the mediator? Diabetes Care 26: 2734-2740

230. Sierksma A, Patel H, Ouchi N, *et al* (2004) Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 27:184-189

231. Kerr D, Macdonald IA, Heller SR, Tattersall RB (1990) Alcohol causes hypoglycaemic unawareness in healthy volunteers and patients with Type 1 (insulin dependent) diabetes. Diabetologia 33: 216-221

232. Pownall HJ, Ballantyne CM, Kimball KT, Simpson SL, Yeshurum D, Grotto AM (1999) Effect of moderate alcohol consumption on hypertriglyceridemia. Arch Intern Med 159: 981-987

233. Burger M, Brönstrup A, Pietrzik K (2000) Alkohol und Krankheiten. Abschlussbericht zum Forschungsvorhaben des Bundesgesundheitsministeriums für Gesundheit. Schriftenreihe des Bundesministeriums für Gesundheit Band 134; NOMOS-Verlagsgesellschaft Baden-Baden

234. Feskens EJM, Kromhout D (1990) Habitual dietary intake and glucose tolerance in middle-aged euglycaemic men. The Zutphen Study. Int J Epidemiol 19: 953-959

235. Feskens EJM, Bowles CH, Kromhout D (1991) Inverse association between fish intake and risk of glucose intolerance in normoglycaemic elderly men and women. Diabetes Care 14: 935-941

236. Colditz GA, Manon JE, Stampfer MJ, Rosner B, Willett WC, Speizer FE (1992) Diet and risk of clinical diabetes in women. Am J Clin Nutr 55: 1017-1023

237. Marshall JA, Haag S, Shetterly S, Hamman RF (1994) Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 17: 50-56

238. Feskens EJM, Virtanen SM, Räsänen L, *et al* (1995) Dietary factors determining diabetes and impaired glucose intolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 18: 1104-1112

239. Salmeron J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC (1997) Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 277: 472-477

240. Liu S, Manson JE, Stampfer MJ, *et al* (2000) A prospective study of whole-grain intake and risk of type 2 diabetes mellitus in US women. Am J Public Health 90: 1409-1415

241. Mann J, Toeller M (2001) Type 2 diabetes: aetiology and environmental factors. In: Ekoe J-M, Zimmet P, Williams R (Eds), The epidemiology of diabetes mellitus. John Wiley & Sons, Chichester and New York, pp 133-140

242. Janket S-J, Manson JE, Sesso H, Buring J, Liu S (2003) A prospective study of sugar intake and risk of type 2 diabetes in women. Diabetes Care 26: 1008-1015

243. D'Agostino RB, Hamman RF, Karter AJ, Mykkanen L, Wagenknecht LE, Haffner SM, for the Insulin Resistance Atherosclerosis Study Investigators (2004) Cardiovascular disease risk factors predict the development of type 2 diabetes. Diabetes Care 27: 2234-2240

244. Schulze MB, Manson JE, Ludwig DS, *et al* (2004) Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA 292: 978-979

245. Pan XR, Li GW, Hu YH, *et al* (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544

246. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindström, Tuomilehto J for the Finnish Diabetes Prevention Study Group (2003) Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52: 2532-2538

247. Laaksonen D, Lindström J, Lakka T *et al* (2004) Physical activity in the prevention of type 2 diabetes: The Finnish Diabetes Prevention Study. Diabetes 54: 158-165

248. McAuley KA, Williams SM, Mann JI, *et al* (2002) Intensive lifestyle changes are necessary to improve insulin sensitivity: A randomised controlled trial. Diabetes Care 25: 445-452

249. Hollick MF (2004) Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79: 362-371

250. Fung TT, Manson JE, Solomon CG, Liu S, Willett WC, Hu FB (2003) The association between magnesium intake and fasting insulin concentration in healthy middle-aged women. J Am Coll Nutr 22: 533-538

251. Lopez-Ridaura R, Willett WC, Rimm EB (2004) Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 27: 134-140

252. Song Y, Manson JE, Buring JE, Liu S (2004) A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women. Diabetes Care 27: 2108-2115

253. Song Y, Manson JE, Buring JE, Liu S (2004) Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 27: 59-65

254. Guerrero-Romero F, Tamez-Perez HE, Gonzalez-Gonzalez G, *et al* (2004) Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diab Metab 30: 253-258

255. Zhao HX, Mold MD, Stenhouse EA, *et al* (2001) Drinking water consumption and childhood-onset type 1 diabetes mellitus in Devon and Cornwall, England. Diabet Med 18: 709-717

256. Van Dam RM, Feskens EJ (2002) Coffee consumption and risk of type 2 diabetes mellitus. Lancet 360:1477-1478

257. Agardh EE, Carlsson S, Ahlbom A, *et al* (2004) Coffee con-sumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women. J Intern Med 255: 645-652

258. Rosengren A, Dotevall A, Wilhelmsen L, Thelle D, Johansson S (2004) Coffee and incidence of diabetes in Swedish women: a prospective 18-year follow-up study. J Intern Med 255: 89-95

259. Salazar-Martinez E, Willett WC, Ascherio A, *et al* (2004) Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 140: 1-8

260. Tuomilehto J, Hu G, Bidel S, Lindstrom J, Jousilahti P (2004) Coffee consumption and risk of type 2 diabetes mellitus among middle-aged Finnish men and women. JAMA 291: 1213-1219

261. Gale EA, Bingley PJ, Emmett CL, Collier T, European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363: 925-931